206 results about "Flu immunization" patented technology

A cross-protective influenza virus vaccine has been designed based on the incorporation of the genetically engineered, highly conserved M2 influenza viral protein optionally in combination with an adjuvant such as a bacterial flagellin protein incorporated into the membrane of a virosome or virus-like particles. Immunogenicity and the breadth of cross protection efficacy are significantly enhanced using multiple copies of the influenza M2 protein as a membrane bound tetramer and/or in combination with a membrane bound adjuvant. A method for vaccinating a subject for influenza A has also been developed that results in broad and improved cross-protection against multiple subtypes of influenza A virus.

The invention discloses a serum-free medium for Madin-Darby canine kidney (MDCK) cell full suspension culture. The serum-free medium for MDCK cell full suspension culture comprises an amino acid part, a vitamin part, an inorganic salt part and other additive parts. The serum-free medium has the beneficial effects that the serum-free medium for MDCK cell full suspension culture, provided by the invention, is high in cell culture density and clear in composition and does not contain animal serum, a downstream product is purified, the product quality is improved, and the serum-free medium is convenient to prepare and use and suitable for large-scale production of influenza vaccines and avian influenza vaccines.

The present invention relates to an artificially synthesized gene optiHA containing codons for chicken partial tropism. Its reading frame contains 1707 bp nucleotides and encodes a total of 568 amino acids. The gene is compatible with H5 subtype highly pathogenic avian influenza virus A/ Goose/GuangDong/1/96(H5N1)[GD/1/96(H5N1)]hemagglutinin (HA) gene has a nucleotide homology rate of 70%, an amino acid homology rate of 100%, and encodes the H5 subtype Hemagglutinin (HA) protein of avian influenza virus GD/1/96 (H5N1). The invention also relates to the application of the gene as an immunogenic gene of H5 subtype influenza DNA vaccine and other genetic engineering vaccines.

The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines.

The invention relates to the technical field of culture medium development and research of biotechnology and discloses a serum-free medium suitable for large-scale production of influenza vaccines. The serum-free medium comprises 23 basic metabolism nutrients, two nucleic acid compounds, 6 vitamins, 9 inorganic salt compounds, a shear force protective agent, two acidity and alkalinity buffer agents, an acidity and alkalinity indicator, 10 virus reproduction promoters and three additives. The conventional preparation method of the serum-free medium comprises the following steps of: dissolving the components in ultrapure water without a heat source so as to prepare the serum-free medium. The using method is a conventional method. The serum-free medium has the beneficial effects that the serum is not contained, the total protein content is lower than 10mg per liter, separation and purification of the product are promoted, and the serum-free medium is suitable for production of influenza vaccines, supports the normal growth and long-term continuous cell culture of animal cells and can be used without adaption; and moreover, because the components are clear, the serum-free medium is convenient to prepare, controllable in cost and suitable for large-scale production of the influenza vaccines.

The invention discloses a nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and preparation method thereof. The vaccine is inactivated vaccine antigen of totivirus, lytic virus, viron or virus-like particles, flue multivalent vaccine antigen is flue pentavalent, namely H1N1, H3N2, B, H5N1 and A (H1N1) or multivalent vaccine antigen combined on the basis at will, or flue multivalent vaccine antigen obtained by containing all the combination of the HA selecting from H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 and H16 and the NA selecting from N1, N2, N3, N4, N5, N6, N7, N8 and N9 subtypes on the basis. The content of flu multivalent inactivated vaccine antigen HA in the vaccine of the invention is 1.0-15.0 Mug/0.2ml/per person, and the vaccine of the invention can effectively prevent routine human flue, high pathogenicity H5N1 avian-human flu, influenza A (H1N1) and infection of other subtype influenza viruses.

The present invention relates to the field of animal virology, and provides a recombinant chicken-origin H9N2 avian influenza virus vaccine strain and a method for isolation, identification and purification of the strain. The invention further relates to a research of biological characteristics of the strain, especially to a research of characteristics of the strain adopted as the vaccine strain,and an evaluation of immune effects of the strain on SPF chickens. The preservation number of the strain is CCTCCNO:V201030. According to the present invention, the antigen variation conditions of the virus strain and other isolated virus strains are represented from the molecular level; after the virus strain is prepared into the vaccine, the prepared vaccine is adopted to immunize the 4 week old SPF chickens, with the protection effect analysis of the homologous H9 influenza wild virus strain and the heterologous H9 influenza wild virus strain, the results show that the influenza virus strain can be adopted as the spare vaccine strain of H9 subtype avian influenza. With the present invention, the spare vaccine strain is provided for prevention of the avian influenza outbreak by using the vaccine, the molecular biology technology program is provided for screen of the avian influenza virus vaccine strain, the molecular biology background is provided for study of the mechanism of animal infection by the avian influenza, and the important public health significance is provided.

The present invention includes novel influenza antigenic formulations and vaccines that comprise influenza M2 peptide and VLPs comprising influenza M2 protein. The invention also includes methods of making and administering the novel antigenic formulation and vaccine. The invention also include methods of inducing immunity to ameliorate and/or prevent influenza infections in a subject.

The invention provides for mosaic influenza virus HA and NA sequences and uses thereof.

Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg influenza virus strain per ml. Components (i) and (ii) can be presented in kit form.

The invention relates to a compound immunoenhancement agent and an application thereof on preparing a vaccine for birds. The compound immunoenhancement agent contains 5ng-10mg/mL of poly IC, 10ng-10mg/mL of muramyl dipeptide, 10ng-5mg/mL of levamisole, 10ng-5mg/mL of resiquimod and 10ng-5mg/mL of imiquimod. After the immunoenhancement agent and H5 hypotype bird flu inactivated vaccine are mixed together, antibody can be produced one week earlier, and the antibody titer is improved above 1.8log2. After chicken are immunized through H5 hypotype bird flu inactivated vaccine, H9 hypotype bird flu vaccine or infectious bronchitis vaccine which contains the compound vaccine immunoenhancement agent, the window phases of the antibody production are shortened, the antibody titer of the vaccine is improved, the immunization duration is prolonged, and the probability of infection disease is reduced.

The invention provides a method for preparing a Vero cell influenza virus vaccine. Seasonal trivalent influenza vaccines and pandemic influenza storage vaccines with qualified quality can be prepared by improving a vaccine purification process, combining hydrophobic chromatography with ion exchange and auxiliarily adopting other purification methods.

The invention discloses an H1N1 subtype swine influenza virus A/Swine/Shanxi/D5/2011 (H1N1) with the preservation number of CGMCC No.5323 and also discloses a vaccine containing the virus. The H1N1 subtype swine influenza virus provided by the invention is not polluted by extraneous pathogeny, has higher multiplication capacity on both a chicken embryo and a cell, shows obvious clinical symptoms after infecting a BALB/c rat and a swine influenza negative piglet and has typical autopsy pathological changes and good immunogenicity, and an oil emulsion inactivated vaccine prepared by using the H1N1 subtype swine influenza virus has 100% of protective efficiency for the attack of a homologous virus after immunizing a pig and serves as a favorable candidate swine influenza vaccine strain.

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.

The invention discloses an influenza A virus Vero cell adapted strain and application thereof. The influenza A virus Vero cell adapted strain is named as A/Yunnan/1/2005Va(H3N2), and the preserving number of the strain is CCTCC NO:V200514. The strain comprises an H3 subgroup hemagglutinin gene, an N2 subgroup neuraminidase gene and 6 internal genes for high yield of characteristic influenza viruses on Vero cells. The blood coagulation titer can be maintained at more than 1,024 by continuous subculturing of the strain on the Vero cells. The strain can be taken as a donor strain and subjected to genetic reassortment with an epidemic strain, or reverse genetics technology is adopted to perform genetic reassortment on the 6 internal genes and 2 surface protein genes of the epidemic strain to obtain the Vero cell adapted strain of the epidemic strain, and finally the adapted strain is used for preparing a Vero cell influenza vaccine or a Vero cell pandemic influenza vaccine.